323 clinical trials
grid
list
download
- Title Organ Phase Statut Major inclusion criteria Contact
- 1206 - HNCG A randomized phase II study to evaluate the efficacy and safety of Chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs) Oral cavity and lips phase 2 Closed metastatic, RECIST 1.1
- 1301-LG 10-day decitabine versus conventional chemotherapy (?3+7?) followed by allografting in AML patients >= 60 years: a randomized phase III study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group Acute leukemia phase 3 Closed 1st line / >= 60 years old / Eligible for standard intensive chemotherapy/ De novo or secondary AML is allowed
- 1367.1 An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit Multiple phase 1 Closed any line, RECIST 1.1
- 1407 GUCC TIGER A Randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high dose chemotherapy using mobilizing paclitaxel plus ifosfamide followed by high-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors Testicles phase 3 Closed Germ cell tumor
- 1479-0001 An open label, Phase I dose escalation trial, with dose confirmation and expansion, of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations. Lung phase 1 Open
-
38RC17.290
Characteristics and Care of Solid Tumor Patients Treated With Immunotherapy Admitted in Intensive Care Unit.
Solid tumors
Closed
Treatment by Immunotherapy <6months
Admission in intensive care - 61186372GIC2002 A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer Multiple phase 1/2 Open
- 8951-CL-0301 A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Stomach - Duodenum-esogastric junction phase 3 Closed Unresecable or metastatic
- AB11002 AB11002 A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib to sunitinib in patients with gastrointestinla stromal tumor after progression with imatinib. Stomach - Duodenum-esogastric junction phase 3 Closed c-Kit positive. Progression under imatinib
- ADRIATIC A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (D933QC00001 - ADRIATIC) Lung phase 3 Closed 4 lines chemotherapy and radiation
- AG013-ODOM-201 A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cancers of the head and neck receiving concomitant chemoradiation therapy Head and Neck phase 2 Closed No prior gene therapy
- AL-TNBC-01 - TENACITY A Phase 2, Multicenter, Open-label, Single arm Study of AL101 Monotherapy in Patients with Notch Activated Triple Negative Breast Cancer Breast phase 2 Closed
- Allo-Shrink An open-label, Phase I study to assess the safety of multiple doses of CYAD-101, administered after standard FOLFOX chemotherapy in patients with unresectable metastatic colorectal cancer Colon phase 1 Closed Unresacable metastasis. RECIST v1.1. Can receive FOLFOX
- AMC303-01 A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin Multiple phase 1/1b Closed any line, RECIST 1.1